

HTANGEL

Keeping you up-to-date on
HTA decisions

Issue 37: May 2026

Cancer approvals dominate May as targeted therapies gain ground across Europe.

This newsletter summarises final decisions from NICE, SMC, HAS & IQWiG from published reports in May 2026.

Good news

Amivantamab, approved for NSCLC in England; **Doxecitin with doxribtimine**, approved for thymidine kinase 2 deficiency in France; and **Enfortumab vedotin**, approved for unresectable or metastatic urothelial cancer in Scotland.

Mixed news

Asciminib, approved as first-line therapy for Ph+ chronic myeloid leukaemia but not second line in Germany; and **Selumetinib**, approved for type 1 neurofibromatosis in adults but not in children in Germany.

Bad news

Avapritinib, not approved for indolent systemic mastocytosis in Germany; **Inebilizumab**, not approved for Ig4-related disease in England; and **Peginterferon alfa-2a**, not approved for polycythaemia vera or essential thrombocythaemia in Scotland.

Approvals

20

Non-approvals

9

HTANGEL

Issue 37: May 2026

Pharmacological Technologies



Scotland
SMC2936

Blood
Polycythaemia vera
PEGINTERFERON
ALFA-2A



Terminated



Scotland
SMC2937

Blood
Thrombocythaemia
PEGINTERFERON
ALFA-2A



Terminated



England
NICE TA1153

Cancer
Biliary tract cancer
ZANIDATAMAB



Approved
with special
conditions



Germany
IQWiG A25-150,
G26-09, A26-40

Cancer
Chronic myeloid
leukaemia
ASCIMINIB



Approved



Germany
IQWiG A25-150,
G26-09, A26-40

Cancer
Chronic myeloid
leukaemia
ASCIMINIB



Not
approved



Germany
IQWiG A26-41, A25-
148

Cancer
Head and neck
cancer
PEMBROLIZUMAB



Approved



Scotland
SMC2925

Cancer
Hodgkin lymphoma
BRENTUXIMAB
VEDOTIN




Terminated



England
NICE TA1158

Cancer
Lung cancer
AMIVANTAMAB



Approved
with special
conditions

HTANGEL

Issue 37: May 2026

Pharmacological Technologies



Scotland
SMC2818

Cancer
Lung cancer
DURVALUMAB

✓ Approved



Scotland
SMC2842

Cancer
Urothelial cancer
ENFORTUMAB
VEDOTIN

✓ Approved



England
NICE TA1150

Cancer
Lung cancer
ENCORAFENIB WITH
BINIMETINIB

✓ Approved
with special
conditions



England
NICE TA1152

Cardiovascular
Myocardial
infarction, Stroke
SEMAGLUTIDE

✓ Approved
with special
conditions



England
NICE TA1156

Cancer
Lung cancer
OSIMERTINIB

✓ Approved
with special
conditions



England
NICE TA1157

Genetic & Metabolic
Duchenne muscular
dystrophy
GIVINOSTAT

✓ Approved
with special
conditions



Germany
IQWiG A26-06

Cancer
Ovarian cancer
MIRVETUXIMAB-
SORAVTANSINE

✓ Approved



France
HAS AP571

Genetic & Metabolic
Thymidine kinase 2
deficiency
DOXECITIN WITH
DOXRIBTIMINE

✓ Approved



HTANGEL

Issue 37: May 2026

Pharmacological Technologies



Germany
IQWiG G26-06

Infection

Bacterial infection
IMIPENEM, CILASTATIN,
RELEBACTAM



Approved



England
NICE TA1155

Neurology

Myasthenia gravis
ROZANOLIXIZUMAB



Approved
with special
conditions



Germany
IQWiG A26-09

Neurology

Neurofibromatosis
SELUMETINIB



Not
approved



Germany
IQWiG A26-33, A25-
147

Neurology

Neurofibromatosis
SELUMETINIB



Approved



England
NICE TA1154

Neurology

**Spinal cord injury,
Spina bifida**
OXYBUTYNIN



Terminated



Germany
IQWiG G26-04

Renal

Glomerulonephritis
PEGCETACOPLAN



Approved



Germany
IQWiG G26-03

Renal

Glomerulopathy
PEGCETACOPLAN



Approved



Scotland
SMC2814

Renal

IgA nephropathy
BUDESONIDE



Approved

HTANGEL

Issue 37: May 2026

Pharmacological Technologies



Scotland
SMC2926

Respiratory
Cough
GEFAPIXANT



Germany
IQWiG A26-28, A25-136

Other
Mastocytosis
AVAPRITINIB



Germany
IQWiG A26-32, A25-145

Respiratory
Rhinosinusitis
TEZEPELUMAB



Scotland
SMC2832

Skin
Prurigo nodularis
NEMOLIZUMAB



England
NICE TA1151

Other
Immunoglobulin G4
disorder
INEBILIZUMAB




HTANGEL

Issue 37: May 2026

Further Information

HTAngel is designed to help keep you up to date with the latest HTA decisions from NICE, SMC, HAS & IQWiG.

Below is a breakdown of the tiles in the newsletter.



At Crystallise we aim to provide an innovative approach to processing information, using software tools to automate processes that are slower and less accurate when done by humans. Our approach provides clients with greater transparency and scope than they could find for the same budget elsewhere. We work with a network of experts and organisations that help us support clients efficiently and effectively, and are proud of our flexible and ingenious way of solving their problems.

For further information about HTAngel contact
newsletter@crystallise.com

To speak to us about our services contact
contact@crystallise.com

